[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:ahrr-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"AHRR Gene",6,5,[8,16,22,28,34,40],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06267729","Study of AZD0754 in Participants With Metastatic Prostate Cancer",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:16:55.892527Z","2026-05-05T02:43:28.077996Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06525298","EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors",[12],"2026-08-26T02:16:45.157238Z","2026-05-05T02:43:26.674524Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT06253130","A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors",[12],"2026-08-26T02:17:14.343713Z","2026-05-05T02:43:28.527433Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":32,"content_modified":33},"NCT06907043","A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.",[12],"2026-08-26T02:16:52.995882Z","2026-05-05T02:43:26.722951Z",{"nct_id":35,"title":36,"phases":37,"status":13,"updated_at":38,"content_modified":39},"NCT07446855","Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced\u002FMetastatic Homologous Recombination Deficient Solid Tumours",[12],"2026-08-26T02:18:41.390601Z","2026-05-05T02:35:31.932505Z",{"nct_id":41,"title":42,"phases":43,"status":45,"updated_at":46,"content_modified":47},"NCT06120491","Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents",[44],"Phase 3","ACTIVE_NOT_RECRUITING","2026-08-03T03:02:32.170340Z","2026-05-05T02:43:29.381320Z"]